Skip to main content
Top
Published in: Rheumatology International 2/2012

01-02-2012 | Case Report

Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene

Authors: Luca Cantarini, Orso Maria Lucherini, Gabriele Simonini, Mauro Galeazzi, Cosima Tatiana Baldari, Rolando Cimaz

Published in: Rheumatology International | Issue 2/2012

Login to get access

Abstract

Systemic juvenile idiopathic arthritis (SJIA) is a disorder characterized by arthritis in children starting before 16 years of age associated with daily high fever, persisting for more than 2 weeks, and at least one of the following clinical features: evanescent cutaneous rash, lymphadenopathy, serositis or hepatosplenomegaly. SJIA patients carry a significantly higher frequency of MEFV mutations, the gene responsible for familial Mediterranean fever, and may be characterized by a more aggressive disease. In this line, we describe a 9-year-old girl affected with SJIA who carried a heterozygous G196W mutation in MEFV. Our patient was characterized by an aggressive disease course, resistance to conventional immunosuppressive agents and developed renal amyloidosis just 2 years after the disease onset.
Literature
1.
go back to reference Petty RE, Southwood TR, Baum J et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25:1991–1994PubMed Petty RE, Southwood TR, Baum J et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25:1991–1994PubMed
2.
go back to reference Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed
3.
go back to reference Lovell DJ (2006) Update on treatment of arthritis in children—new treatments, new goals. Bull Hosp Jt Dis 64:72–76 Lovell DJ (2006) Update on treatment of arthritis in children—new treatments, new goals. Bull Hosp Jt Dis 64:72–76
4.
go back to reference Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479–1486PubMedCrossRef Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479–1486PubMedCrossRef
5.
go back to reference Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998–1006PubMedCrossRef Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998–1006PubMedCrossRef
6.
go back to reference David J (1991) Amyloidosis in juvenile chronic arthritis. Clin Exp Rheumatol 9:73–78PubMed David J (1991) Amyloidosis in juvenile chronic arthritis. Clin Exp Rheumatol 9:73–78PubMed
7.
go back to reference Immonen K, Savolainen HA, Hakala M (2007) Why can we no longer find juvenile idiopathic arthritis-associated amyloidosis in childhood or in adolescence in Finland? Scand J Rheumatol 36:402–403PubMedCrossRef Immonen K, Savolainen HA, Hakala M (2007) Why can we no longer find juvenile idiopathic arthritis-associated amyloidosis in childhood or in adolescence in Finland? Scand J Rheumatol 36:402–403PubMedCrossRef
9.
go back to reference Aganna E, Hawkins PN, Ozen S et al (2004) Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 5:289–293PubMedCrossRef Aganna E, Hawkins PN, Ozen S et al (2004) Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 5:289–293PubMedCrossRef
10.
go back to reference Yeniay BS, Karaca NE, Yuksel SE, Midyat L, Kutukculer N (2007) Juvenile psoriatic arthritis carrying familial Mediterranean fever gene mutations in a 14-year-old Turkish girl. J Dermatol 34:344–348PubMedCrossRef Yeniay BS, Karaca NE, Yuksel SE, Midyat L, Kutukculer N (2007) Juvenile psoriatic arthritis carrying familial Mediterranean fever gene mutations in a 14-year-old Turkish girl. J Dermatol 34:344–348PubMedCrossRef
11.
go back to reference Ayaz NA, Ozen S, Bilginer Y et al (2009) MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 48:23–25CrossRef Ayaz NA, Ozen S, Bilginer Y et al (2009) MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 48:23–25CrossRef
Metadata
Title
Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene
Authors
Luca Cantarini
Orso Maria Lucherini
Gabriele Simonini
Mauro Galeazzi
Cosima Tatiana Baldari
Rolando Cimaz
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1331-7

Other articles of this Issue 2/2012

Rheumatology International 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.